# ClearPoint Neuro, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/ClearPoint Neuro, Inc.). ## Overview ClearPoint Neuro, Inc. develops and commercializes image-guided neurosurgery platforms used for minimally invasive procedures in the brain. Its business combines capital equipment and disposable products for the ClearPoint system with consulting and service revenue tied to biologics and drug delivery programs that aim to deliver therapies directly to targeted brain tissue. ## Products & services • ClearPoint system for MRI-guided neurosurgical procedures • SmartFrame Array Neuro Navigation System • SmartFrame OR Stereotactic System • ClearPoint Prism Neuro Laser Therapy System • Biologics and drug delivery consulting services • Preclinical and clinical trial support for brain delivery programs - **Neurosurgery navigation and therapy products** (55%) — Capital and disposable products used for image-guided brain procedures, including the ClearPoint platform and related navigation systems. - **Biologics and drug delivery services** (40%) — Consulting, protocol design, and execution support for customers developing gene, cell, and other brain-delivery therapies. - **Laser therapy and adjunct commercialization products** (5%) — Therapy-related offerings such as the Prism laser system and newer product launches that expand the platform's clinical use cases. - ClearPoint system for MRI-guided neurosurgical procedures - SmartFrame Array Neuro Navigation System - SmartFrame OR Stereotactic System - ClearPoint Prism Neuro Laser Therapy System - Biologics and drug delivery consulting services - Preclinical and clinical trial support for brain delivery programs ## Customers ClearPoint sells to hospitals and neurosurgeons for clinical procedures, while its biologics and drug delivery business serves pharmaceutical companies, biotech firms, academic institutions, and customer-sponsored CROs. These partners use ClearPoint-related products and services to support preclinical work, clinical trials, and eventual commercialization of therapies that must reach targeted brain tissue. The customer base is therefore split between clinical users buying devices and research/development customers buying expertise and workflow support. - **Clinical neurosurgery users** (primary) — Hospitals and surgeons buy ClearPoint navigation and therapy products for minimally invasive brain procedures. - **Biologics and drug delivery partners** (primary) — Pharma and biotech customers buy consulting and workflow support to develop therapies delivered into the brain. - **Academic research institutions** (secondary) — Universities and research centers use the platform for preclinical and translational neuroscience work. - **Contract research organizations** (secondary) — CROs use ClearPoint-related services to support customer-sponsored studies and trial execution. - Hospitals and neurosurgeons using ClearPoint in brain procedures - Pharmaceutical companies developing gene and cell therapies - Biotech firms testing targeted brain-delivery approaches - Academic institutions running translational neuroscience studies - Customer-sponsored CROs needing protocol and trial support ## Geography The company is headquartered in the United States and received FDA clearances for its core products there, making the U.S. the anchor market for commercialization. It also has CE-marked products for Europe, which broadens the addressable market for its neurosurgery platform and supports international adoption. Geography matters because regulatory approvals, reimbursement, and clinical adoption differ by region, especially for novel brain-delivery therapies. - United States is the core commercial and regulatory market - FDA clearances support U.S. product sales and adoption - CE marking enables sales in Europe for selected products - International growth depends on regulatory approvals and clinical uptake - Brain-delivery programs face region-specific trial and approval pathways ## Strategy ClearPoint is focused on expanding its commercial neurosurgery platform while building a larger biologics and drug delivery business around gene and cell therapy programs. Management views the biologics segment as the largest growth opportunity, but it depends on customer trial progress, regulatory approvals, and continued partner relationships. The company is also broadening its product set with newer systems such as SmartFrame OR and Prism to deepen clinical use and recurring revenue. - **Grow biologics and drug delivery partnerships** (medium-term) — This is management's largest stated growth opportunity and can create recurring service and product demand. - **Expand ClearPoint platform commercialization** (short-term) — Recurring product sales from the installed base help stabilize revenue and support operating leverage. - **Broaden therapy applications** (medium-term) — New indications and products increase the number of procedures and addressable customers. - Expand recurring product revenue from the ClearPoint installed base - Grow biologics and drug delivery services with pharma and biotech partners - Convert preclinical programs into clinical and commercial opportunities - Launch new products such as SmartFrame OR and Prism Laser Therapy - Use partnerships to capture upside from successful therapies ## Risks The business depends on clinical and regulatory success in highly uncertain brain-therapy programs, so delays or failures in FDA review can directly reduce future demand. ClearPoint also remains loss-making and has relied on external financing, which increases execution and funding risk as it scales commercialization. In addition, the company faces integration risk from the planned IRRAS merger and the typical adoption, reimbursement, and competition risks seen in medical devices. - **Regulatory delay or failure for cell and gene therapies** [high] — A large part of growth depends on customers' therapies reaching approval and commercialization. - **Continued operating losses and financing dependence** [high] — The company has not achieved profitability and has historically funded operations with equity and debt. - **Merger integration risk** [medium] — The planned IRRAS transaction may create integration costs, employee retention issues, and liability surprises. - **Commercial adoption risk** [medium] — New neurosurgical products require surgeon training, workflow integration, and clinical acceptance. - Customer therapies may fail in clinical trials or regulatory review - FDA policy changes can delay or block biologics-related demand - The company has a history of operating losses and funding needs - Merger integration with IRRAS could distract management and add costs - Medical device adoption depends on physician workflow and reimbursement ## Accounting Revenue is split between product sales and service/consulting revenue, so investors should watch how the company recognizes each stream and whether mix shifts affect margins. Quarterly results can be volatile because product sales, service activity, and partner-driven trial timing do not move evenly through the year. The company also carries significant accumulated losses, so estimates around going-concern-like funding needs, merger-related liabilities, and any future impairment or acquisition accounting will matter. - **Revenue recognition by product vs service line** — Product sales are mostly ClearPoint-related; service revenue is tied to biologics programs. - **Project-based and partner-driven timing** — Can make revenue and operating leverage difficult to forecast. - **Merger-related valuation and liabilities** — Could affect goodwill, intangible assets, and future impairment risk. - Product and service revenue recognition can shift reported mix and margins - Quarterly timing of partner projects can create uneven revenue patterns - Accumulated losses increase sensitivity to financing and liquidity assumptions - Merger accounting may create fair value and liability measurement judgments - Potential impairment risk exists if acquired or developed assets underperform --- *Last updated: 2026-04-28T19:58:11.260426+00:00*